The FDA approved an adjuvant regimen combining pembrolizumab with belzutifan for adults with high-risk clear cell kidney cancer following surgery. The approval is supported by a Dana-Farber study backing the FDA decision, according to the report. Belzutifan is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, and pembrolizumab is an immune checkpoint inhibitor. Together, the combination targets two biologic pathways implicated in clear cell RCC progression. For biotech and translational teams, the decision signals continued appetite for multi-mechanism adjuvant strategies in earlier-stage oncology, particularly where tumor hypoxia pathways can add to immune checkpoint biology.